ABCL - Earnings call 3 2023 | AbCellera Biologics Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to AbCellera's Third Quarter 2023 Business Update Conference Call. My name is Kate, and I will facilitate the audio portion of today's interactive broadcast. [Operator Instructions]At this time, I would like to turn the call over to Tryn Stimart, AbCellera's Chief Legal and Compliance Officer.

You may proceed.

Tryn Stimart

Thank you. to Quarter welcome Business and afternoon, AbCellera's XXXX Third Update. Good

after that with pleased in as issued Relations today, website.With to our are the find us you our market can which have AbCellera's to Hansen, call The release me Officer. webcast the announced We Investor results of this call Carl Executive and Financial AbCellera's today you are refer today on closed President; Chief Officer the a we press we slide call. presentation contains Chief during Dr. on and will the Andrew discuss Booth, portion

are of phone and this you section on wish portion may along you Relations slide so do the If on presentation, the following website. to our the Investor access of

who the safe web.This have contain portion you there you pursuant aware that will streaming the post performance. statements are Private harbor filings to factors webcast, the impact the forward-looking presentation to be are management's able our be expectations current questions and Please of a XXXX. and of may on subject future review that Securities Act accessed via and of not may those risk uncertainties. provisions our SEC delay Litigation that statements please For certain based Any forward-looking be risks Reform for of to could the

dollars.Now that Our to presentation U.S. and pleased the dollars am referred all Investor Note Carl during SEC on to call Dr. website. available call filings are I are to Relations Hansen. our today our over turn

Carl L. Hansen

studies. this AbCellera-led from highlight that assets X Thanks, are into quarter we is Tryn. IND-enabling advancing programs The

enable the the treatment in atopic best-in-class initiated is inflammation. our PK being discovered EQRx autoimmunity therapy ABCLXXX has less September XXXX. to Revolution with part dermatitis We ligand with and and asset, co-development been first for designed Sanofi positive potency, new as program differentiation. At class.Our acquired present, second endocrine is developed and undisclosed and than of by indications was program as recently The was potential a the annual indication for follow EQRx conditions. potential targets of and we segment collaboration be during metabolic We provides other and more at which an in asset, had ownership OXXX to ABCLXXX of potential developed market a after this developability It one that amlitelimab, has for took ABCLXXX ABCLXXX of this the first ABCLXXX frequent first-in-class by a dosing, with in II to target is in Medicines. $X the which which believe against be in billion in readout being providing a the assets of Phase potential a potential estimated sales. evidence therapy to an has

announce risk. next we for studies.We an XX expected, studies that caution development when this committed only things clinic. internal an and in would additional from would details and Channel we For We them the advantage will indication strategic more program first-in-class ABCLXXX this derived our will to to platform ABCLXXX reasons, XX first it move aligned the anticipate to ABCLXXX only submissions carry of and pipeline IND-enabling said, is as reaches the in anticipate and technology leveraging into we our candidates to months IND our expertise strategy AbCellera-led XXXX. leading GPCR Ion with forward have of of and progress both if significant them asset platform, create is an assets. we disclose once from That IND

first-in-class potential we trials. programs, therapies. efficacy we programs growing and provide assets both we that these generate and data to get programs, that potential see the clinical believe early future to potential from for evidence early For the X -- will both best-in-class We efficacy get can see repeatedly

the breadth will be in advance anticipate our Thus, bandwidth into the capital an partnership discovery of the part to the In selective assets strategy.Turning we we Given ourselves. we announced with partnering partnering. generating more forward have of we a or will to ones than activities, in bring new out-licensing area clinic important oncology. September, and our to Incyte and the remain we expect working of

still We against has from candidates including active. our agreement, rights a existing programs Under the Regeneron GPCR programs, its advance also expanded target. collaboration completed one antibody original Regeneron. with X Other exercised to are

in In also yesterday, to collaboration Prelude quarter, ADCs, antibody we conjugates, in with novel addition or completed to the Therapeutics the drug X announced codevelop partnerships oncology. a precision

the working out be team degraders.In to last with therapeutics are this focused key we protein with on molecule program summary, I year. that small first objectives a that the new to like Prelude excited armed of over on developments quarter laid are We development highlight would with business with aligned the class of antibodies

platform and co-development said a we IND-enabling X XXXX. from Ion at at platform First, in we from X would and candidate elect Channel least our studies for least GPCR candidate

With strategic on that the would ABCLXXX we achieved high-value partnerships. said focus advance commitment and ABCLXXX, we we to have milestone.Second,

like Prelude strategy. are with groups Incyte deals and Regeneron, Our this aligned with

be this in we We T-cell as SITC to expected. and data platform tomorrow, engager continue enter Diego. also our advance platform San expected XXXX. new transaction science at the significant into our presenting team and said development And to The in will a would of progress

we haven't we partnerships.And as its to strategic it increasing will and I a basis over a assets in hand TCE in our both transaction yet, completed generate our Andrew? that, discuss with to for have Andrew to While internal conviction potential platform, financials.

Andrew Booth

Thanks, Carl.

during our key the highlight progress quarter the third First, XXXX. of let on metrics business me made

cumulative on of in worked starts. starts number be to as total programs partnered quarter taking program given And of a discovery will reminder, a us the new X XXX any we quarter, irregular. This

we've the unique of programs partners. XX We programs. the and in programs trailing the contract XXX to under X with XX contract agreed XXXX Over ended new work third partner-initiated months, XX under on quarter started quarter with

on rather deal the focus continue As we've we to stated in strategic volume. past, on partnerships than

fee programs clinic in the total molecules cumulative do include revenue initiated examples we payments molecule of term.Turning metrics potential NovaRock business QX XX of not revenue. initiated more XXXX. a long-term advance was revenue is of to molecules partnerships program. by XXXX, where fee to of on AbCellera consistent of clinic. focus approximately a by our into additional in reduction driven saw for larger the as has that an work of This of quarter fees QX are of compares key longer the downstream the Our internally.In increasing This discovery midterm and in view in our our the $X on in million, specific the on milestone in value clinic Revenue royalty growing million relating from almost entirely near research $X approximately strategic AbCellera fees list and research We with the partnership research participation revenue programs.

there related milestone some year in licensing amounts expenses. unlike ago, to and This quarter's no includes And revenue fees. no payments earned to also a were royalties small the quarter.Turning operating

marketing, QX compared of in compared QX million the at in continuing and research net million We're $XX general platform of over just good year, administration, the the quarter operating expenses in expenses reflects and business to increase previous earnings million, roughly of of period reporting loss our $XX of $XX of just QX earnings. investment million. $X.X the and growth in our the for of absence continued approximately This QX This And roughly investments reflecting $X revenues previous reflects were execution, to million under representing present XXXX, third were year. the over internal Our to a in over increase year. compares program approximately of a in development million $XX the In loss for were in the previous leverage.Looking and development royalty XXXX. $XX sales programs. expenses were $XX same of quarter the the million the that million and just

and to the of we per million. $X.XX earnings share, for loss of activities X work quarter's used first months and activities cash third basic operations results XXXX flow short-term note, absence expect cash.As of to at of would roughly million as often of terms invested this operating irregular the flows. treasury to the the we approximately part Of and of quarter, of we quarterly in out a Operating regular million revenues, on royalty used investment marketable In company. share from a invest diluted strategy, we over growth capabilities in our $XX our basis.Looking be $XXX per In and cash in negative $XX securities. continue the a have

when our reminder, GMP cash than programs our in million by of equipment billion and runway. part and million on does year our large in Strategic $XXX separately to million our reported previously quarter for our the need we X is from $XXX GMP available government And All into up approximately holdings. and liquidity have sheet operating QX CMC we increase with XXXX respect driven million, long-term of is continuing by unused clinic visibility include of Investments activities million course, of work investments. Our in are, not the plant with to year successful sources invested total equipment $XX nondilutive co-funded $X amounted and excellent equivalents $XXX capabilities. balance securities.We position With as and on our other manufacturing capital establish financials.With been This secured plant over investment of to Altogether, in towards over the show in Canada's million other property, sheet. capital. X capital continue $XX to total This our at net including property, Fund. a ago approximately investment expenditures, build-out historically approximately cash, Innovation these the we raising have portion our months the liquidity. facility and the in more $XX the of and Government of finished balance available funding, ongoing over marketable and approximately activities first

and continue we Operator? fund next X be We your and years overall well questions. to liquidity to the that platform of investments to with beyond happy take have we'll pipeline that, sufficient growth.And believe

Operator

from Bratzel question [Operator line the Instructions] Piper The of Allison will with Sandler. first be

Allison Bratzel

help to bar confidence what update. on really SITC? posters just a maybe that for have looking order potential Thanks partners trigger more for frame guess the partnership. I what's pull to T-cell the you TCE speak on your really platform is in for and best-in-class in expect think the the at engager are platform the you can see could really we tomorrow just And

on would latest be setup Your thoughts really there the helpful.

Carl L. Hansen

here. take Carl that. Allison, Thanks, to Sure. Happy

on continued progress focus presentations R&D have The we the SITC to here. So great really X developments on make platform.

cell the capability generate One of specific expressed see get differentiated of able are and up surface that inside highly that against that to and peptide antibodies array as opens are of advancement the presented a targets MHC being tumors. the but the the platform a of them towards to that targets. highly is to We broad cell,

has shows being thesis, been by cytokine of we we've and So something highlight on-target affinity and affinity our to That's TCEs, not being cases toxicity.The for you one that diversity alone combining allows do in the able that epitope compared cannot can pursued that forward of think to hands, to antibodies as solves problems the been of original reduce also to find has about of continued key obtain targets time. the recent you is in to to able off-tumor the are broad very release. something many or and and was other that mixture big that binders release in the have toxicity binders both benchmarks compelling being that of able That antibodies. we in data being and is which that clearly SITC, a more from the see push evidence but OrthoMab tested CDX the far just killing that some decouple we're excited it is killing at where with And the particular, the shows profiles that of platform very demonstration cell clearest specific change that a shown obtain in importantly, against. problem.What's cytokine existing you using we and our that dose-limited have as

relationships of right think, I always built transaction, engaged fronts, are going So in well. last with it's And all to difficult over I going all of we The that have a year. the timing the top is the direction. think very groups predict. on is But and

Operator

with next Karnauskas question line from Truist. be The Robyn will of the

Robyn Karnauskas

can I'm address that you able answer, broadly one as not you but be may going the more to your capabilities. maybe ask to it to

this liquor address can they molecule may just safe you it Regeneron this And achievable? things with optimal. are design think won't about And that be challenges maybe that? target ] or address that safe How morning more facing make a OXXX [ if lot on differently to maybe index how So suboptimal mentioned are they're their may not call ] Dupixent. have a competitive be specificity versus for not improve The could be its therapeutic these that reasons, drug [indiscernible], broadly thinking companies [ I capabilities specifically because molecule of you where better? you a

Carl L. Hansen

that. to happy take I'm Robyn. Sure,

literature this can pathways is able for think in the reset suggests in I to to different T-effector array we it ABCLXXX, multiple class, a a T that with to few That homeostasis and is, wide we in So but line and which We're it compelling and is OXXX from help that compelling not our robust it for memory atopic pathway.The regulatory recent but that that there a that scientific makes that your a see that body it One cells dermatitis, of a that. do cascade few readout very not with system. bringing evidence excited proliferation pathway in to also affect activation disease, inflammation immune which that about antibody are completely only is way associated of was the cells is as T with a cells for Sanofi things to reasons. can say question looks It inflammation. mentioned interact just against in related the that suppresses and forward of conditions a a about that. ligand. we're one for Maybe

which to So looks it study effective. what you'd expect that And the time, be looks is effects interesting in that the you be safe. what to seem It to better immune able system. was if to is get were reset over

in very believe, is dermatitis in for exciting also potential reasons, one and a we of atopic other first we the I has broad pathway it. all space conditions.ABCLXXX, the as is in those So think behind and growing said,

think potency Now inside But half-life you it. people way of come have be we give of provides their disclosed. one the the based pipeline to the has engineered we we this know first they combination in and have think and in don't that what and would haven't behind disclosures, it to an that potential one a that dosing. developability And advantage formulation on

Dupixent you an compares, we're Regeneron obviously excited amazing mentioned particular drug. why So one.As that that's about it I think Dupixent. and is

inflammation, interest Our and the every finding is not view that in responds patient therapies that combining the even future. to therapies in and is are there available, a in of perhaps lot alternatives

a So this exists of rather we the that example don't but see as an all, opportunity in huge as space. that negative at

Robyn Karnauskas

not make to that that use they like broad? I understand mean, can you the a -- too use I technology to can just think you because as that too now. is the dirty, just do hot market current a have AbCellera are right their what you better upon a target would is Like on view And follow-up, are -- current word they're OXXX ones improve going that ones to or are

and I'm ] So, you the can back show up maybe technology well, [ the what then queue. getting in as

Carl L. Hansen

antibody. So That so that a depleting course, have is OXXX. antibody to Amgen. get to antibody of clear, developed we being antibody be is OXXX There going by that is, is ligand, an an OXXX not

be have our causes antibody presenting T an on been cause the much. T evidence The cells. on And cells. not it's antibody I on is an antibody antigen and So is which has some engaged may which ablation non-ablating. too ligand, that that, want engineered mean T but cells, we speculate There's binds those OXXX to don't that to rather presented I presented cells OXXX, problems. that that of

to Function Fc mentioned, has And big see it got from has developed with Sanofi.So not that antigen made presenting and of disclosure by similar the So amlitelimab, molecules. problem problem Sanofi see with a being cells, don't that killing We being toxicity. we're getting that the advanced most we course, it which the of the dirty. they've information a does result which I in is very don't

So inflammation to conditions. effective lot and one looks our profile of quite knowledge, a one a other and clean and in that has like this that's potential

Operator

question the be Tan of next with Sachs. The will from Goldman Andrea line

Andrea Tan

on here. Carl, question atopic pursue maybe can to to as more speak decision one initial the for the XXX Strategically, you you derm indication.

could this Just curious might is. If you asset one given where indications where advantage have how crowded landscape an are to also that but there bring of it other being first-in-class. sense make mechanistically, forward

Carl L. Hansen

efficacy. because showing in one places a say, data most of I That's atopic get shows -- early trial. easier the derm also clinical Phase is already that a dermatitis mean to out there great IIa or is the place in let's It's I data the obvious is question. efficacy,

main based what this that's a the just high is sense has the pathway in as reason.We atopic in of other feel you right from this So seen we've other dermatitis, not conditions. our now. and on probably likelihood space, that clinic but the in mentioned. working, That's a competitive very But molecules

what's a we now, there. not the clinical trials. There's important development to of is getting right start going early of in lot that here consideration to this delay molecule and between and most thinking and the So be through through

some a find a that also we is accelerate partner big development to but different enabled advantageous that something have highly a in best and potential may perhaps worth variety probably that think ], would and be so change point, company. a done by clinical that it [ molecule large this would at And it's classes is because of I saying to

steps. priority to subsequent clinical to concept. said, proof of So to that get as and now the would feeling early that development now is of right current through get right But be in this terms our I

Andrea Tan

you bring to remind of a Can clinical just programs the development. maybe which your through on to follow-up And there. your us advance Perfect. would maybe extent I these own, them willingness you guess,

Carl L. Hansen

This is and return address is we committed to Every on I. the ahead and question that we priorities risk/reward thought intercepted needs through It's and time different normally we business we're different that opportunity, the possible different and program I lot, we program and considered what's evaluate and going it's not as strategy of investment. with was Every course, on do costs, programs? that, best to a this that would best into trials, framed to as own is merits. single we right for it's often now, to further that we ABCLXXX ABCLXXX the My things get have be strategy and where are its internal internal get we get off think And for have that. to steam best be to the that. Happy that it is bring challenges think of table what lines, company end do different programs. business that your a could a point, wrong think for there'll -- Sure. the the that I to one will path. allocation would of get the progress, take operational to we right it will clinical to Phase opportunities.The full if the advance After strategic development. about And capital way different in response but

Andrew Booth

about for significant some received speaking, into funding receiving this government Andrea, as funding it that quite efficient can do well, That announcement in we the add and government make I included year amount funding if us to us the is that molecules to advance some allow of move there Phase that. just, had we would And Andrew capital earlier molecules. I

consistent strategy. completely with that announcement and is this that So

Operator

the line Stephen The of with Stifel. next from will be Willey question

Stephen Willey

ligand the procuring antibody. on congrats And OXXX

tumor said there that been the the think antibody want here?And to birthed you discovery about different a that the target they high conventional pace guess could contemplate good here can requiring just can't of develop of Or tumor you this internalization the antibody across companies. antibody Prelude I targeted just efficient you their hoping that? bit to, it's degrader variety kind deal, degrader. chemical can a they're that I of kind a top think this see to collaboration then that purposes you guess platform given for is, want you a interesting both delivering version variety think you administer makes is tumors relevant different which scaffolds have little I types sometimes by Does to that are towards I of multiple you what do more a notion SMARCAX relevant is of think, of respect ADCs? with kind a a I some of take specific level degrader that antigens. the that of type, on SMARCAX same in a angle probably to on of chemo talk market ] just and [ different

Carl L. Hansen

Great questions.

collaboration. start by me excited we're saying Let the that about

on are our the have have to We a small will conjugate together SMARCA. and you rightly that be first and coming need, the new This think strategic emphasized teams X partnerships. molecule X-star antibody out, strategic certainly of an focus development we It on to exciting sides antibody of related you be deep X degrader. as the a we that antibody pointed is what expertise will in that for class an program, enable have very partnership one conjugates.The molecule is experienced development

may what about have effective. that mentioned The in release. to press even exactly to think the an you do be I do been question antibody want

going needed. that about preclinically together you effect we're that molecule out. the first cancers, that at into of a what tumors.So thing require ultimately you the certainly want But that to some the do index this different be that the is antibody. and hypothesis to to the a that the degrader particular is would There you is go proof the and think We've show different programs. deliver the small can for is figure in enough assays working good therapeutic to be got in get I might degrader potential

to many very like antibody The much collaboration degraders that also be could has not where use into but other to the is that more small concept targeted instrument sort other be be molecules, one the just be of table. and pathways. of conjugates at to big the beginning is the And I've successful the drug on a this, about for a poison, potential to bring space could as the as Prelude chance we're the And team values we're is that into of it that molecular go also to new something entities blend and cytotoxics, and that's at we at able confidence and progresses. And precision learning So teams forward.So working we'll one, get do both got excited a difference hopefully -- for you makes we'll patients. to this a update will be able be together.

Operator

next with Souda will from Partners. line Puneet Leerink question be the of The

Puneet Souda

questions of here. couple A

first for one do there. data them? start here maybe simple see and Maybe When the Just a for XXX. early we XXX let's just of both

Carl L. Hansen

Yes.

some -- So some data ahead time I'm data exactly we provide filing. as update with IND but line the of you not for I it that comes along. now, that will expect preclinical on right XXX, sure we'll

in for mentioned, not indication. or would it the do target XXX, the to think of we For reasons, business interest even the disclose as be strategic the wiser

that to our so close until to keep IND. chest one, And it going we're to gets

Andrew Booth

INDs the his prepared Carl be And XXXX. mentioned remarks, in sorry, in Puneet but -- would

Puneet Souda

yes. Yes,

that outlay towards for to early obviously, you into what of GMP of level to lot a investment sort that or the drug that's of second XXXX facility. remind the work you to this going -- of that's of here that's be have of of have that if the just facility, there's So that CapEx you before sort my -- Andrew, filed question sort a stage the IND, be needs opening can us kind have related is, you And done. is

going the So fill or there's situation. how you that is impact you set how bit all in that the overall maybe CDMO to a in facility. priority that at about you just set are talk going for who's think going today, be to of priority -- if the maybe overcapacity facility capacity as GMP look in an landscape you you about 'XX? for then the to to Does at can And manufactured of sort what

Carl L. Hansen

Carl, here. in miss Maybe I'll fill start, if and something. can I Andrew

of programs, possible. ABCLXXX be for not it's we up first both forward will That's facility the in quickly third-party be running. imperative capability our as since and these for manufacturing we come And manufacturing the believe all, XXXX. first year a X XXX these and should and we ABCLXXX, the filed programs, The as having move expect same manufactured So by for that online is to XXX. INDs

to through very program internal the first are The GMP facility likely be AbCellera programs.

your We also the but be is we that firms of of macro was, expect last of I is think do Perhaps there some environment does that, from internally.The with strategic affect question partnerships, a CDMO. large lot expecting use to that our the that say, come capabilities obviously, that are we'll as slowdown, part doing that have today. it a market programs not not manufacturing you in there's a broadly tracking let's CDMO facility effect

not be ourselves. developed going have we molecules we're taking So on inbound that not to

the at that the manufacturing internally or So put to into facility at AbCellera been or partners. have that AbCellera we have that is molecules with expect either pipeline in been done collaboration done

And we've the what in good got sight that, be line to used based will on facility. a I as of so think

Puneet Souda

us then if sort and If of front you could there? there? bit it. the thinking update just you this just that wanted what's competitive sort a on antibody question. a discovery Beacon by And The of Bruker. Could maybe clarify. changes the landscape your tendential on I on changed hands litigation now maybe acquired Got the And is to platform left for a make sure

Andrew Booth

let that take me Puneet, sure, one. Yes,

been in an it -- then our are time So litigation to Bruker what we'll full of now in stayed our and have invalidate outcome stood know, at to to and started went we process over the the with force. -- and of at XXXX. to and pursue which as wait patents the a see litigation underway. in up been course and maybe IP attempt courts of litigation couple and to the was now during is the years would to patents, IPR Bruker, expect Berkeley continue has That We that declared XXXX Lights ago, intend the hands proceeding that you favor response -- up and through that the continue that into but legitimate is, the even the the was now unstated stood the now of

Operator

be will question next from The Cowen. line the Mah with of Steven

Poon Mah

Great.

partner partners. seeing us And of new inbound weighted and give given of that little color more that inbounds bit on the what smaller type the the us potential can your the some macro color on discussions with adds, side. Prelude give one I some ask and or environment? given a discussions you level smaller. on if the Maybe these On to larger And are was you're player,

Carl L. Hansen

Yes.

Carl, that. happy here, to So take

First, on for and be think been you that analyst the has a biotech bare some market a to time. don't biotech have macro, for I see to is this

our are out there companies slowdown of that what results is that opportunities new have, and volume. that And financing in ocean prioritizing for not that companies. years, new been companies all formation that is preserving we in capital. absolutely the said, a last for communicating deal are is They of a the that consistently smaller X means programs. partnering.So are So focus of on The

X where that finding to unique insight we stake we a Prelude strategic have a that and with opportunity that such bringing therapeutic. things. either or It And company as in is on them, that together company have means significant get that means is bringing a is able of focus we're make Our therapeutic found technology unique and in conviction to one that target a strategic biology. that a partnerships we a great

the second is of companies large that's deeper and first relationship So setting like category strategic.The Regeneron, category with of the engagements building very Incyte. well-enabled companies, some and companies up like

R&D. They're It are that firms robust from firms. means at quite to bigger we The means at in line examples bigger are invest quarter volume. the that. with this in this that primarily looking That looking that up So continuing market. also we're lower

think going to just a to don't strategy. I with continue we're on that, so of we're going lot and that our see And impact

Poon Mah

then capability, is more. if And GMP asked that manufacturing you as Prelude you're downstream the discussions? any just to that in? just And I out by curious know building changes have And if there the been manufacturing Great. the of to I again, impacting Okay. start wanted -- that one maybe helped can facility? building because biologics capabilities to partnership I was Has also, GMP biologics your the collaboration timing

Andrew Booth

Yes, the I'll question, of that it's Andrew part Steve, take first here.

manufacturing. invest continue in we the So GMP CMC and to both

to happening our think batches first sort for the in CMC plan have and engineering development batches pilot XXXX. of I is

And in that ultimately the So And GMP interest facility that I then first cell maybe will mean be that could next batches I'll discovery programs of through manufacturing own but Carl year. those XXXX. comment be would more little to go of that would today think That that. facility bit CMC capabilities. be and And of that on the line we're also development qualification support on starting first the batches -- let batches, from the a -- partners, Phase that the production does the is the advanced engineering when to is I. our

Carl L. Hansen

front-end going of have AbCellera. and clinical programs time optimization, attractive the part lead CDMO GMP companies, capabilities huge that release jockey science, CMC, to to very frankly, hassle of internally, substantially discovery, a except amount in where is that having they're with of firms way and relationships shrink slots to bigger working variety a an coming that provides much we of manufacturing and of new too a translational some the manage the the in that for the and space from their to altogether make when exists, particularly Not that with with to It development. not sure with set are the venture flexibility. through integration equipped discussions, add smaller creation the or firms Yes. up in start of obviously, particularly networks idea a And early in, are right

why place it. as we'll lift in put a together, we're confident in So are that have Andrew It's now said. we're very that and that see investing strategic it advantage, heavy XXXX, we as important crossing a that's right to but in it

Operator

the be will from Malcolm BML. Hoffman of question next The with line

Malcolm Hoffman

enable benchmark to ask what the dosing PK to ABCLXXX. to those molecules that other wanted ] able or you they first more been on greater are. about AbCellera? Evan. with Malcolm [ on potency noted color in for frequent designed and molecules. I less than development It's Are has Are molecule provide benchmark molecules approved the from assets

Carl L. Hansen

Sure.

have said concentration PK dosed less of a believe developability, it that I it's that allow be and frequently and selected to what clear, existing benchmark to particularly been we formulations is potency, combination meaning high be molecules. than engineered would to So

that Amongst of course, the one mentioned the out are, clinical ones testing including I them earlier. assets, We disclosed are are the there.

Operator

Thank are so the call turn registered over back you. final At to in the there questions Carl additional no for will I time, this queue, remarks.

Carl L. Hansen

X keeping call time future you exciting Thank forward candidates big you calls, well. look AbCellera development today. for advancing wish you, This in joining remains and everyone, the for an forward. to our on milestones with We updated

Operator

Thank your and you disconnect That now concludes may call. your all conference today's lines. for participation, you

AbCellera Biologics (ABCL) 2 Nov 232023 Q3 Earnings call transcript